高流量鼻导管治疗与无创通气治疗AECOPD合并急性高碳酸血症性呼吸衰竭:随机对照试验Meta分析
该Meta分析系统检索PubMed、Embase、Cochrane Library和clinicaltrials.gov,无语言限制,纳入4项RCT共486例AECOPD合并高碳酸血症性急性呼吸衰竭患者,比较HFNC与NIV。结果显示两组全因死亡率(RR 0.97,95%CI 0.56-1.68)和插管率(RR 1.67,95%CI 0.99-2.83)无统计学显著差异;NIV组治疗切换率(RR 2.60,95%CI 1.54-4.38)和治疗失败率(RR 1.64,95%CI 1.04-2.60)显著更低。作者认为更多接受HFNC的患者治疗失败并切换至NIV,可能掩盖了HFNC劣于NIV的事实。
要点
- AECOPD合并高碳酸血症性急性呼吸衰竭:HFNC与NIV全因死亡率无显著差异(RR 0.97,95%CI 0.56-1.68)。
- 插管率两组无统计学显著差异(RR 1.67,95%CI 0.99-2.83,95%CI跨1)。
- NIV组治疗切换率显著更低(RR 2.60,95%CI 1.54-4.38,HFNC组更高)。
- NIV组治疗失败率显著更低(RR 1.64,95%CI 1.04-2.60,HFNC组更高)。
- 作者认为更多HFNC患者治疗失败后切换至NIV,可能掩盖HFNC劣于NIV的事实。
适用人群与场景
- 慢性阻塞性肺疾病急性加重(AECOPD)合并高碳酸血症性急性呼吸衰竭患者。
研究设计与关键结果
- 研究类型:随机对照试验的Meta分析,共纳入4项RCT,486例患者。
- 检索数据库:PubMed、Embase、Cochrane Library、clinicaltrials.gov,无语言限制。
- 全因死亡率:HFNC与NIV无统计学显著差异(RR 0.97,95%CI 0.56-1.68)。
- 插管率:HFNC与NIV无统计学显著差异(RR 1.67,95%CI 0.99-2.83)。
- 治疗切换率:NIV组显著低于HFNC组(RR 2.60,95%CI 1.54-4.38,以HFNC为参照)。
- 治疗失败率:NIV组显著低于HFNC组(RR 1.64,95%CI 1.04-2.60,以HFNC为参照)。
证据类型、等级与局限
- 证据类型:随机对照试验的Meta分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,更多接受HFNC氧疗的患者出现治疗失败并切换至NIV,可能掩盖HFNC在AECOPD合并高碳酸血症性急性呼吸衰竭患者中劣于NIV的事实。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Guidelines recommend the use of noninvasive ventilation (NIV) and high-flow nasal cannula (HFNC) in patients with chronic obstructive pulmonary disease (COPD) and hypercapnic acute respiratory failure (ARF). It is unclear whether HFNC is noninferior to NIV in terms of the rate of tracheal intubation or mortality. This meta-analysis aimed to compare the efficacy of HFNC and NIV in patients with AECOPD and hypercapnic ARF.
METHODS: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of hypercapnic AECOPD with HFNC, compared with NIV, were reviewed. Estimated effects of included studies were pooled as risk ratios (RRs), with 95% confidence intervals (CIs).
RESULTS: Four RCTs (enrolling 486 patients) met the inclusion criteria. There was no statistically significant difference in all-cause mortality (RR 0.97, 95% CI 0.56 to 1.68), and intubation rate (RR 1.67, 95% CI 0.99 to 2.83) between the two groups. The treatment switch rate (RR 2.60, 95% CI 1.54 to 4.38) and treatment failure rate (RR 1.64, 95% CI 1.04 to 2.60) were significantly lower in NIV groups.
CONCLUSIONS: Compared with NIV, HFNC was not associated with increased mortality and intubation rate. More patients receiving HFNC oxygen therapy experienced treatment failure and switched to NIV, which may mask the fact that HFNC is inferior to NIV in patients with AECOPD and hypercapnic ARF.
参考来源
- Qin J, Wang G, Liao Y, et al. High flow nasal therapy versus noninvasive ventilation for AECOPD with acute hypercapnic respiratory failure: a meta-analysis of randomized controlled trials. Ann Intensive Care. 2025. PMID: 40360910. doi:10.1186/s13613-025-01480-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。